Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLEAN-1: ADI-001 in B Cell Malignancies
NCT04735471Phase 1Terminated
- Sponsor
- Adicet Bio
- Start
- Mar 2021
- Primary completion
- Feb 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of prulacabtagene leucel in follicular lymphoma (FL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL) and 3 more (3 arms), sponsored by Adicet Bio. Primary endpoints: Incidence of Dose Limiting Toxicities at Day 28 and Proportion of Adverse Events at 1 year. Started Mar 2021; status: terminated.
02
Drugs
prulacabtagene leucel
03
Conditions
follicular lymphoma (FL)mantle cell lymphoma (MCL)marginal zone lymphoma (MZL)primary mediastinal large B-cell lymphoma (PMBCL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04735471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04735471.